- Home
- PHUN vs CALC Comparison
PHUN vs CALC Comparison
Compare PHUN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- CALC
- Stock Information
- Founded
- PHUN 2009
- CALC 2011
- Country
- PHUN United States
- CALC United States
- Employees
- PHUN N/A
- CALC N/A
- Industry
- PHUN EDP Services
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- CALC Health Care
- Exchange
- PHUN Nasdaq
- CALC Nasdaq
- Market Cap
- PHUN 53.3M
- CALC 48.1M
- IPO Year
- PHUN N/A
- CALC N/A
- Fundamental
- Price
- PHUN $2.77
- CALC $3.12
- Analyst Decision
- PHUN Buy
- CALC Strong Buy
- Analyst Count
- PHUN 2
- CALC 2
- Target Price
- PHUN $7.75
- CALC $14.50
- AVG Volume (30 Days)
- PHUN 209.9K
- CALC 72.1K
- Earning Date
- PHUN 11-06-2025
- CALC 11-12-2025
- Dividend Yield
- PHUN N/A
- CALC N/A
- EPS Growth
- PHUN N/A
- CALC N/A
- EPS
- PHUN N/A
- CALC N/A
- Revenue
- PHUN $2,400,000.00
- CALC N/A
- Revenue This Year
- PHUN N/A
- CALC N/A
- Revenue Next Year
- PHUN $53.29
- CALC N/A
- P/E Ratio
- PHUN N/A
- CALC N/A
- Revenue Growth
- PHUN N/A
- CALC N/A
- 52 Week Low
- PHUN $2.22
- CALC $1.42
- 52 Week High
- PHUN $14.60
- CALC $5.65
- Technical
- Relative Strength Index (RSI)
- PHUN 55.14
- CALC 52.23
- Support Level
- PHUN $2.42
- CALC $2.62
- Resistance Level
- PHUN $2.81
- CALC $3.73
- Average True Range (ATR)
- PHUN 0.10
- CALC 0.36
- MACD
- PHUN 0.04
- CALC -0.01
- Stochastic Oscillator
- PHUN 89.74
- CALC 44.59
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.